Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for INCY
103.74
-1.75 (-1.66%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 101.55 - 106.67
52 week 43.86 - 121.70
Open 106.18
Vol / Avg. 0.00/953,657.00
Mkt cap 18.89B
P/E     -
Div/yield     -
EPS -0.23
Shares 179.04M
Beta 0.93
Inst. own 95%
Aug 4, 2015
Q2 2015 Incyte Corp Earnings Call - 10:00AM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Incyte Corp Earnings Release - 7:00AM EDT - Add to calendar
Jun 11, 2015
Lilly and Incyte Webcast to Discuss Baricitinib Phase III Data
May 22, 2015
Incyte Corp Annual Shareholders Meeting
May 19, 2015
Incyte Corp at UBS Global Healthcare Conference
May 14, 2015
Incyte Corp at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Incyte Corp at Deutsche Bank Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -11.53% -9.48%
Operating margin -4.35% -0.94%
EBITD margin - 7.16%
Return on average assets -8.70% -6.64%
Return on average equity - -
Employees 588 -
CDP Score - -

Address

1801 Augustine Cut off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company's compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Officers and directors

Herve Hoppenot President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Julian C. Baker Independent Vice Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Reid M. Huber Executive Vice President, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Barry P. Flannelly Executive Vice President - Business Development and Strategic Planning
Age: 57
Bio & Compensation  - Reuters
Richard S. Levy M.D. Executive Vice President, Chief Drug Development and Medical Officer
Age: 57
Bio & Compensation  - Reuters
Wenqing Yao Ph.D. Executive Vice President - Discovery Medicinal and Process Chemistry
Age: 52
Bio & Compensation  - Reuters
Steven H. Stein M.D. Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters